IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Status:	Completed
Conditions:	Blood Cancer, Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	12/31/2017
Start Date:	January 2012
End Date:	July 2016

A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

The purpose of this study is to test the safety and tolerability of IMGN529 in patients with
relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

Inclusion Criteria:

- Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal
zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell
lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL).

- Adequate organ function

- ECOG ≤ 2

- Recovered or stabilized from prior treatments.

Exclusion Criteria:

- Allogeneic stem cell transplantation

- Pregnant or lactating females

- Known central nervous system, meningeal or epidural disease including brain metastases

We found this trial at

sites

Oncology Institute of Southern Switzerland

Bellinzona,

from

Bellinzona,